3D Biomatrix Inc. launched its Perfecta3D Hanging Drop Plates at the end of last year and recently secured more international distribution partners. It also has just raised $725,000 from 22 investors, according to recent regulatory filings. A call to the company wasn’t immediately returned.
According to the company, its products enable researchers to gather information about a drug’s behavior in early discovery and allows them to identify early on compounds that would fail later in the process.
Three-dimensional cell growth products better mimic the structure and cell-cell and cell-matrix interactions of the in-vivo environment than traditional 2-D surfaces do, but industry has been slow to adopt tools for 3-D cell growth, the company notes in a blog post. But there’s plenty of competition in the space — Nacalai USA, Life Technologies and Nano3D Biosciences are a few of the other companies making 3-D cell cultures.
Ann Arbor, Michigan-based 3D Biomatrix was also recently awarded a STTR grant from the NIH to develop a high throughput assay for metastatic prostate cancer using its drop plates. This work will facilitate the development of better drugs by providing a high throughput assay that mimics prostate cancer metastasized to bone, the company says.
Formed in 2010, 3D Biomatrix is part of the University of Michigan’s Venture Accelerator.